Biomea Fusion (BMEA) news
Recent news
Biomea Fusion topline 26-week primary endpoint data from Covalent-211 expected in Q1 2027
AInvest Wire · 7d agoImportantBiomea Fusion shares slump after offering is priced
AInvest Wire · Oct 7, 2025Biomea Fusion to transition into diabetes and obesity medicines company
AInvest Wire · Jan 13, 2025Truist cuts Biomea Fusion to hold, cites clinical hold uncertainty
Truist cuts Biomea Fusion to hold, cites clinical hold uncertainty Biomea Fusion, a biotech company based in Redwood City, California, has faced a significant setback in its diabetes research as the US Food and Drug Administration (FDA) placed a full clinical hold on its ongoing Phase I/II trials…
AInvest Wire · Jun 11, 2024ImportantBiomea Fusion, Inc. shares lost 55% after it announced a clinical hold on its ongoing Phase I/II clinical trials of its covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes.
Biomea Fusion, Inc. shares lost 55% after it announced a clinical hold on its ongoing Phase I/II clinical trials of its covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes. Biomea Fusion, Inc. (BMEA) has faced a significant setback in its ongoing efforts to develop novel treatments for…
AInvest Wire · Jun 7, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.